BofA raised the firm’s price target on Elevance Health (ELV) to $370 from $330 and keeps a Neutral rating on the shares. Managed Care payment year 2027 stars results were largely in line with expectations as a number of MCOs preannounced their ratings early, though Centene (CNC) and Elevance “showed nice improvement in their stars, albeit off of depressed bases,” the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health price target raised to $420 from $342 at Mizuho
- Elevance Health price target raised to $395 from $373 at Barclays
- Elevance Health price target raised to $398 from $360 at Guggenheim
- Elevance Health price target raised to $412 from $330 at Wells Fargo
- Sector Spotlight: UnitedHealth shareholder proposes split of CEO, chair role